Clinical Trials

Trial Name Description
Keynote 564 Renal Dr. E. Winquist
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy
Checkmate 901 GU Dr. E. Winquist
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
PCS 6 Dr. D'Souza
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI).
PCS IX Dr. Michael Lock
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial (PCS IX)
IND.232 GU Dr. E. Winquist
A Phase II Study of Durvalumab (MEDI4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer
MISTER Dr. Eric Winquist
Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer.
PR.19 Dr. David D'Souza
"not yet open" A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer.
CEC-CTC Renal Dr. A. Allan
Prospective validation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) as prognostic biomarkers in clear cell renal cancer
CLEAR Dr. Eric Winquist
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carci
IND.223 Dr. Eric Winquist
A Phase II Study of Palbociclib, A CDK 4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer.
REC.3 Dr. Kylea Potvin
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantanib [NSC#761968], Crizotinib [NSC#749005], Savolitinib [NSC#785348], and Sunitinib [NSC#736511])in Metastatic Papillary Renal Carcinoma (PAPMET).
Renal mTor Dr. M. Haeryfar
Regulation of T cell responses by inhibitors of mammalian target of rapamycin (mTOR)
FASTR 2 GU Dr. B. Bauman
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
OZM-053 GU Dr. Belal Ahmad
A Phase II, Multi-Centre Study of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
TRITON 2 Dr. Scott Ernst
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
TRITON 3 Dr. Scott Ernst
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
IND.234 Dr. Eric Winquist
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study.

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada